TRIAL OF MK-458 CONTROLLED-RELEASE FORMULATION IN PARKINSON'S DISEASE

MK-458 控释制剂治疗帕金森病的试验

• 批准号: 3887084
• 负责人: GEORGE F WOOTEN
• 金额: --
• 依托单位: UNIVERSITY OF VIRGINIA
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3887084
• 关键词: adrenergic agents; antiparkinson drugs; clinical trials; dosage; human subject; human therapy evaluation; neuromuscular disorder chemotherapy

MK-458 (HPMC) is a new, potent, long-acting anf highly-selective D2 dopamine receptor agonist which, in a 30-day open trial, demonstrated marked anti-parkinson efficacy. We propose a 6-month, open treatment study to ascertain the long-term efficacy, tolerability, and safety of MK- 458 as a substitution for sinemet in fluctuating parkinsonian patients.

MK-458（HPMC）是一种新型、强效、长效、高选择性的D2 多巴胺受体激动剂，在30天的开放试验中， 显著的抗帕金森疗效。 我们建议进行为期6个月的开放治疗 确定MK的长期疗效、耐受性和安全性的研究- 458作为波动性帕金森病患者的辛奈美替代品。